前列腺癌最新诊疗指南.pdf

Prostate cancer: diagnosis and treatment Issued: January 2014 NICE clinical guideline 175 .uk/cg175 NICE has accredited the process used by the Centre for Clinical Practice at NICE to produce guidelines. Accreditation is valid for 5 years from September 2009 and applies to guidelines produced since April 2007 using the processes described in NICEs The guidelines manual (2007, updated 2009). More information on accreditation can be viewed at .uk/accreditation © NICE 2014 Prostate cancer: diagnosis and treatment NICE clinical guideline 175 Contents Introduction 4 Drug recommendations 5 Patient-centred care 7 Key priorities for implementation 8 Information and decision support for men with prostate cancer, their partners and carers 8 Assessment 8 Localised and locally advanced prostate cancer 9 1 Recommendations 12 1.1 Information and decision support for men with prostate cancer, their partners and carers 12 1.2 Assessment 14 1.3 Localised and locally advanced prostate cancer 16 1.4 Men having hormone therapy 23 1.5 Metastatic prostate cancer 26 2 Research recommendations 30 2.1 Prognostic indicators 30 2.2 Androgen deprivation therapy and/or brachytherapy added to radiotherapy for men with intermediate- and high-risk localised non-metastatic prostate cancer 30 2.3 Local salvage therapies in men with biochemical relapse after radiotherapy 31 2.4 Bisphosphonates and denosumab to treat osteoporosis 31 2.5 Duration of exercise to combat fatigue in men having androgen deprivation therapy 32 3 Other information 33 3.1 Scope and how this guideline w